TISSUELAB
Biofabrication platform for laboratory-created tissues and organs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | N/A | - | |
| Total Funding | 000k | ||
TissueLabs is a biotech company that provides a biofabrication platform for creating tissues and organs in a laboratory setting. The company was founded by Dr. Gabriel Liguori, who serves as the CEO, and Emerson Moretto is the co-founder and CTO. Dr. Liguori's personal experience with congenital heart disease and subsequent career as a medical doctor with a Ph.D. in Cardiovascular Regenerative Medicine directly inspired the company's mission. He identified a gap between the potential of regenerative therapy and its practical application and founded TissueLabs to bridge this divide.
The company initially started in Brazil in 2019 but moved its headquarters to Switzerland in 2021 to be closer to European markets. It now operates out of a biofabrication hub in Bellinzona, Switzerland, with another location in Miami, USA. TissueLabs' business model centers on democratizing biofabrication by providing accessible and affordable tools to the global scientific community. Its client base includes academic institutions, pharmaceutical companies, and research organizations across more than 30 countries. The company generates revenue by selling its platform components, which include hardware, consumables, and software.
The core products include a line of advanced 3D bioprinters like the entry-level TissueStart™, the high-resolution TissueRay™, and the flagship TissuePro™ for large-scale projects. Complementing the printers is a portfolio of proprietary biomaterials, branded MatriXpec™, which are tissue-specific hydrogels formulated to mimic the extracellular matrix of various human tissues. These products are used for a range of research applications, including drug discovery, disease modeling, personalized medicine, and regenerative medicine, with the ultimate goal of producing bio-artificial organs for transplantation. While the technologies have future clinical potential, all products are currently for research use only. The company's long-term vision is to create the first transplantable bio-artificial heart.
Keywords: biofabrication, 3D bioprinting, tissue engineering, regenerative medicine, biomaterials, hydrogels, organ-on-a-chip, artificial organs, 3D cell culture, drug discovery, biomedical research, tissue models, cardiovascular research, organ transplantation, bioprinters, MatriXpec, life sciences, biotechnology, tissue-specific bioinks, personalized medicine